Thermo Fisher Scientific expands St. Louis manufacturing for complex biologic treatments
Increased capability to produce medicines for challenging diseases including cancer
Increased capability to produce medicines for challenging diseases including cancer
The company had submitted a comprehensive Corrective and Preventive Action (CAPA) plan in September 2022
Biocon will be responsible for obtaining regulatory approval for Liraglutide, and thereafter, for the manufacture and supply of the product in the Canadian market
Sugammadex Injection is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide
Lokavant provides clinical trial intelligence
NRT offers 50% higher success rate in quitting smoking compared to unassisted attempts
Tolvaptan Tablets (RLD Jynarque) had estimated annual sales of USD 287 million in the U.S. (IQVIA MAT August 2023)
VaxTRIALS Adds a New Latin America Base and Greater Vaccine Research Depth
This integrated care offering is a step forward in our vision of providing an effective continuum of care for patients
Subscribe To Our Newsletter & Stay Updated